Aardvark Therapeutics Common Net Income
| AARD Stock | 12.28 0.39 3.08% |
As of the 12th of February 2026, Aardvark Therapeutics shows the Downside Deviation of 4.87, mean deviation of 3.86, and Risk Adjusted Performance of 0.0836. Aardvark Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aardvark Therapeutics value at risk, and the relationship between the jensen alpha and semi variance to decide if Aardvark Therapeutics is priced correctly, providing market reflects its regular price of 12.28 per share. Given that Aardvark Therapeutics has jensen alpha of 0.5747, we suggest you to validate Aardvark Therapeutics Common's prevailing market performance to make sure the company can sustain itself at a future point.
Aardvark Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aardvark Therapeutics' valuation are provided below:There are over one hundred one available fundamental signals for Aardvark Therapeutics Common, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Aardvark Therapeutics' prevailing performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 155.1 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -18.5 M | -19.5 M | |
| Net Loss | -18.5 M | -19.5 M | |
| Net Loss | (1.83) | (1.93) |
Aardvark | Net Income | Build AI portfolio with Aardvark Stock |
Analyzing Aardvark Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Aardvark Therapeutics's current valuation and future prospects.
Latest Aardvark Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Aardvark Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Aardvark Therapeutics financial statement analysis. It represents the amount of money remaining after all of Aardvark Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Aardvark Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aardvark Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (20.59 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Aardvark Net Income Regression Statistics
| Arithmetic Mean | (14,241,933) | |
| Coefficient Of Variation | (20.87) | |
| Mean Deviation | 1,864,360 | |
| Median | (13,564,000) | |
| Standard Deviation | 2,971,606 | |
| Sample Variance | 8.8T | |
| Range | 13.4M | |
| R-Value | (0.38) | |
| Mean Square Error | 8T | |
| R-Squared | 0.15 | |
| Significance | 0.13 | |
| Slope | (226,112) | |
| Total Sum of Squares | 141.3T |
Aardvark Net Income History
Other Fundumenentals of Aardvark Therapeutics
Aardvark Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Aardvark Therapeutics is extremely important. It helps to project a fair market value of Aardvark Stock properly, considering its historical fundamentals such as Net Income. Since Aardvark Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Aardvark Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Aardvark Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Aardvark diversify its offerings? Factors like these will boost the valuation of Aardvark Therapeutics. If investors know Aardvark will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aardvark Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aardvark Therapeutics requires distinguishing between market price and book value, where the latter reflects Aardvark's accounting equity. The concept of intrinsic value - what Aardvark Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aardvark Therapeutics' price substantially above or below its fundamental value.
Understanding that Aardvark Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aardvark Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aardvark Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Aardvark Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aardvark Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aardvark Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Aardvark Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Aardvark Therapeutics Common or generate 0.0% return on investment in Aardvark Therapeutics over 90 days. Aardvark Therapeutics is related to or competes with Assembly Biosciences, Zura Bio, Nautilus Biotechnology, Eupraxia Pharmaceuticals, Caribou Biosciences, Enanta Pharmaceuticals, and Tenaya Therapeutics. Aardvark Therapeutics is entity of United States More
Aardvark Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aardvark Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aardvark Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.87 | |||
| Information Ratio | 0.0784 | |||
| Maximum Drawdown | 38.95 | |||
| Value At Risk | (8.66) | |||
| Potential Upside | 9.35 |
Aardvark Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aardvark Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aardvark Therapeutics' standard deviation. In reality, there are many statistical measures that can use Aardvark Therapeutics historical prices to predict the future Aardvark Therapeutics' volatility.| Risk Adjusted Performance | 0.0836 | |||
| Jensen Alpha | 0.5747 | |||
| Total Risk Alpha | 0.0203 | |||
| Sortino Ratio | 0.0933 | |||
| Treynor Ratio | (0.75) |
Aardvark Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0836 | |||
| Market Risk Adjusted Performance | (0.74) | |||
| Mean Deviation | 3.86 | |||
| Semi Deviation | 4.36 | |||
| Downside Deviation | 4.87 | |||
| Coefficient Of Variation | 1082.94 | |||
| Standard Deviation | 5.8 | |||
| Variance | 33.61 | |||
| Information Ratio | 0.0784 | |||
| Jensen Alpha | 0.5747 | |||
| Total Risk Alpha | 0.0203 | |||
| Sortino Ratio | 0.0933 | |||
| Treynor Ratio | (0.75) | |||
| Maximum Drawdown | 38.95 | |||
| Value At Risk | (8.66) | |||
| Potential Upside | 9.35 | |||
| Downside Variance | 23.76 | |||
| Semi Variance | 19.03 | |||
| Expected Short fall | (4.05) | |||
| Skewness | 1.72 | |||
| Kurtosis | 7.92 |
Aardvark Therapeutics Backtested Returns
Aardvark Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Aardvark Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0869, which signifies that the company had a 0.0869 % return per unit of risk over the last 3 months. By analyzing Aardvark Therapeutics' technical indicators, you can evaluate if the expected return of 0.51% is justified by implied risk. Please makes use of Aardvark Therapeutics' Downside Deviation of 4.87, risk adjusted performance of 0.0836, and Mean Deviation of 3.86 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aardvark Therapeutics holds a performance score of 6. The firm shows a Beta (market volatility) of -0.7, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Aardvark Therapeutics are expected to decrease at a much lower rate. During the bear market, Aardvark Therapeutics is likely to outperform the market. Please check Aardvark Therapeutics' semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Aardvark Therapeutics' price patterns will revert.
Auto-correlation | -0.11 |
Insignificant reverse predictability
Aardvark Therapeutics Common has insignificant reverse predictability. Overlapping area represents the amount of predictability between Aardvark Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aardvark Therapeutics price movement. The serial correlation of -0.11 indicates that less than 11.0% of current Aardvark Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.11 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 1.23 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Aardvark Net Interest Income
Net Interest Income |
|
Based on the recorded statements, Aardvark Therapeutics Common reported net income of (20.59 Million). This is 106.03% lower than that of the Pharmaceuticals sector and 129.39% lower than that of the Health Care industry. The net income for all United States stocks is 103.61% higher than that of the company.
Aardvark Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aardvark Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aardvark Therapeutics could also be used in its relative valuation, which is a method of valuing Aardvark Therapeutics by comparing valuation metrics of similar companies.Aardvark Therapeutics is currently under evaluation in net income category among its peers.
Aardvark Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Aardvark Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Aardvark Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Aardvark Fundamentals
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 148.76 M | ||||
| Shares Outstanding | 21.77 M | ||||
| Shares Owned By Insiders | 14.55 % | ||||
| Shares Owned By Institutions | 54.74 % | ||||
| Number Of Shares Shorted | 1.77 M | ||||
| Price To Book | 2.24 X | ||||
| EBITDA | (22.65 M) | ||||
| Net Income | (20.59 M) | ||||
| Total Debt | 779 K | ||||
| Book Value Per Share | 5.63 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 10.03 X | ||||
| Earnings Per Share | (2.53) X | ||||
| Target Price | 32.64 | ||||
| Number Of Employees | 33 | ||||
| Market Capitalization | 274.56 M | ||||
| Total Asset | 77.51 M | ||||
| Retained Earnings | (58.33 M) | ||||
| Working Capital | 69.21 M | ||||
| Net Asset | 77.51 M |
About Aardvark Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aardvark Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aardvark Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aardvark Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aardvark Therapeutics is a strong investment it is important to analyze Aardvark Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aardvark Therapeutics' future performance. For an informed investment choice regarding Aardvark Stock, refer to the following important reports:Check out You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Pharmaceuticals sector continue expanding? Could Aardvark diversify its offerings? Factors like these will boost the valuation of Aardvark Therapeutics. If investors know Aardvark will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aardvark Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Aardvark Therapeutics requires distinguishing between market price and book value, where the latter reflects Aardvark's accounting equity. The concept of intrinsic value - what Aardvark Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Aardvark Therapeutics' price substantially above or below its fundamental value.
Understanding that Aardvark Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aardvark Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Aardvark Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.